CROI 2016 Program at a Glance

Program and Agenda

456 Multiple-Dose Treatment With Rifabutin Reduces the Exposure of Doravirine Sauzanne Khalilieh 1 ; KellyYee 1 ; Rosa Sanchez 1 ; Rachael Liu 1 ; Li Fan 1 ; Maureen Martell 2 ; Radu Pop 2 ; Heather Jordan 3 ; Marian Iwamoto 1 1 Merck&Co, Inc,Kenilworth,NJ,USA; 2 PharmaMedicaRsr, Inc, Mississauga,ON,Canada; 3 PharmaMedicaRsr, Inc,St.Charles,MO,USA 457 Pharmacokinetics of Anti-TB Drugs in HIV-Infected and -UnInfected ChildrenWith TB Agibothu KupparamHemanth Kumar 1 ; Geetha Ramachandran 1 ; T. Kannan 1 ; P.K. Bhavani 1 ; S. Ramesh Kumar 1 ; N. Ravichandran 2 ; S. Kalpana 3 ; G. N. Sanjeeva 4 ; Dipti Agarwal 5 ; Soumya Swaminathan 1 1 Natl Inst forRsr inTuberculosis,Chennai, India; 2 GovernmentHospof ThoracicMed,Chennai, India; 3 InstofChildHlth,Chennai, India; 4 Indira Gandhi InstofChildHlth,Bengaluru, India; 5 SarojiniNaiduMedColl, Agra, India 458 Optimal Use of Efavirenz in HIV+/ TB+ Coinfected Children Aged 3 to 24 months Carolyn Moore 1 ; Pearl Samson 2 ; Edmund Capparelli 3 ; Mutsawashe Bwakura-Dangarembizi 4 ; Patrick Jean-Philippe 5 ; Nahida Chakhtoura 6 ; Alex Benns 7 ; Bonnie Zimmer 7 ; Chivon McMullen-Jackson 8 ; Ellen G. Chadwick 9 1 Cntr for InfectiousDiseaseRsr inZambia,Lusaka,Zambia; 2 HarvardSch ofPH,Boston,MA,USA; 3 UnivofCaliforniaSanDiego,SanDiego,CA, USA; 4 UnivofZimbabwe,Harare,Zimbabwe; 5 HenryM. JacksonFndn for theAdvancementofMilitaryMed, Inc,Rockville,MD,USA; 6 Eunice KennedyShriverNICHD,Bethesda,MD,USA; 7 FrontierSci&TechRsr Fndn, Inc,Amherst,MA,USA; 8 BaylorCollofMed,Houston,TX,USA; 9 NorthwesternUniv,Chicago, IL,USA 459 Interaction of Darunavir/Ritonavir and Darunavir/ Cobicistat With Rifampicin In Vitro Owain Roberts ; David J. Back; Saye Khoo; Andrew Owen; Marco Siccardi UnivofLiverpool,Liverpool,UK 460 HIV-1 Attachment Inhibitor Prodrug BMS-663068: PK Assessment With Rosuvastatin Ishani Landry; BlisseVakkalagadda; Susan Lubin; Michael Hesney; Jian Wang; Frank LaCreta; Timothy Eley Bristol-MyersSquibb,Princeton,NJ,USA 461LB Early Evidence of Antiviral Activity and Safety of ABX464 in HIV Treatment-Naïve Patients Didier Scherrer 1 ; Jean-Marc Steens 2 ; Supparatpinyo Kuanchai 3 ; RatanasuwanWinai 4 ; Kiat Ruxrungtham 5 ; Regine Rouzier 6 ; JamalTazi 7 ; Paul Gineste 8 ; Hartmut Ehrlich 8 ; Robert Murphy 9 1 ABIVAX,Montpellier,France; 2 ABIVAX,Paris,France; 3 Rsr Inst forHlth Sciences,ChiangMaiUniv,ChiangMai,Thailand; 4 SirirajHosp,Bangkok, Thailand; 5 HIV-NAT,ThaiRedCrossAIDSRsrCntr,Bangkok,Thailand; 6 CapRsr,Phoenix,Mauritius; 7 UnivofMontpellier,Montpellier,France; 8 ABIVAXSA,Paris,France; 9 NorthwesternUniv,FeinbergSchofMed, Chicago, IL,USA

Session P-I1 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM Preclinical Studies of Activity and Resistance 462 A Quantitative Model of ART Efficacy Explains the Clinical Success of Dolutegravir Sarah B. Laskey 1 ; Robert Siliciano 2 1 JohnsHopkinsUniv,Baltimore,MD,USA; 2 HowardHughesMed Inst, Baltimore,MD,USA 463 HIV-1 Transcription Inhibition by New p300 Inhibitors Kotaro Shirakawa 1 ; Melanie Ott 2 ; EricVerdin 2 1 KyotoUniv,Kyoto, Japan; 2 Gladstone InstofVirologyand Immunology, SanFrancisco,CA,USA 464 Maturation Inhibitor BMS-955176: Activity Against PI-Resistant Clinical Isolates Neelanjana Ray 1 ;Tianbo Li 2 ;Tricia Protack 2 ; Zeyu Lin 2 ; Petronella M. van Ham 3 ; Carey Hwang 1 ; Mark Krystal 2 ; Monique Nijhuis 3 ; Max Lataillade 2 ; Ira B. Dicker 2 1 Bristol-MyersSquibb,Princeton,NJ,USA; 2 Bristol-MyersSquibb, Wallingford,CT,USA; 3 UnivMedCntrUtrecht,Utrecht,Netherlands 465 Resistance Pathways for Potent and Broadly Active HIV-1 Maturation Inhibitors Emiko Urano 1 ; Sherimay D. Ablan 1 ; Justin A. Kaplan 1 ; Nishani Kuruppu 1 ; David E. Martin 2 ;Theodore J. Nitz 2 ; CarlT.Wild 2 ; Eric O. Freed 1 1 NCI,Frederick,MD,USA; 2 DFHPharma, Inc,Gaithersburg,MD,USA 466 Maturation Inhibitor BMS-955176: Integrated Model of Polymorphic Antiviral Responses Zeyu Lin; Joseph Cantone; Hao Lu; Beata Nowicka-Sans;Tricia Protack; Dieter Drexler; Mark Cockett; Mark Krystal; Alicia Regueiro-Ren; Ira Dicker Bristol-MyersSquibb,Wallingford,CT,USA 467 Reduction of SIV-Mediated Immune Activation by p38 MAPK In Vivo Inhibition Omkar Chaudhary 1 ;Vivek Narayan 1 ; RonaldVeazey 2 ; Anna Aldovini 1 1 BostonChildren’sHosp,HarvardMedSch,Boston,MA,USA; 2 TulaneNatl PrimateRsrCntr,Covington,LA,USA 468 PBMC From Patients on Chronic Treatment With Dasatinib Are Resistant to HIV Infection Mayte Coiras 1 ; Mercedes Bermejo 1 ; Javier Garcia-Perez 1 ; Benjamin Descours 2 ; Juan Ambrosioni 3 ; Nuria Climent 4 ; Monsef Benkirane 2 ; José M. Miro 3 ; Montserrat Plana 4 ; José Alcamí 1 1 InstdeSaludCarlos III,Madrid,Spain; 2 InstdeGenetiqueHumaine, Montpellier,France; 3 HospClinic-IDIBAPS,UnivdeBarcelona,Barcelona, Spain; 4 IDIBAPS,Barcelona,Spain 469LB Efficacy of an Engineered Bispecific Anti-HIV Antibody in Humanized Mice Anastasia Lanzi 1 ;Yaoxing Huang 1 ; JianYu 1 ; Chasity D. Andrews 1 ; XinYao 1 ; LilyTsai 1 ; Mili R. Gajjar 1 ; Michael Seaman 2 ; Neal N. Padte 1 ; David D. Ho 1 1 AaronDiamondAIDSRsrCntr,NewYork,NY,USA; 2 HarvardMedSchool, Boston,MA,USA

Poster Listings

CROI 2016 111